EGFR and breast carcinoma: Hudelist et al. [108] have shown that immunocytochemical detection of the phosphorylation of Y845 and other tyrosine residues in EGFR can be useful for predicting the clinical outcome of breast cancer patients undergoing anti-HER2/Neu antibody treatment.